Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

14.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Destabilization of Microtubules01:45

Destabilization of Microtubules

2.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pseudokinase-converting mutation in protein kinase C alpha drives chordoid glioma by pathway rewiring.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

Blood advances·2026
Same author

Reactivation of the silenced <i>BASP1</i> gene suppresses oncogenic WNT signaling in human colorectal cancer cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells.

Molecular oncology·2025
Same author

CDK6 kinase inhibition unmasks metabolic dependencies in BCR::ABL1+ leukemia.

Cell death & disease·2025
Same author

Impact of protein and small molecule interactions on kinase conformations.

eLife·2024

Related Experiment Video

Updated: Aug 2, 2025

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.2K

Kinase perturbations redirect mitochondrial function in cancer.

Omar Torres-Quesada1,2, Sophie Strich1, Eduard Stefan1,2

  • 1Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria.

Bioenergetics Communications
|April 21, 2023
PubMed
Summary

Protein kinases regulate cell processes, and their dysfunction causes cancer. Kinase inhibitors can have off-target effects on mitochondria, impacting cancer drug specificity. Mitochondrial bioenergetics may predict these effects.

Keywords:
cancerdrug off-target effectskinase inhibitorskinasesmitochondriasignaling

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Related Experiment Videos

Last Updated: Aug 2, 2025

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Protein kinases are crucial in cell signaling, controlling proliferation, cell cycle, and metabolism.
  • Dysfunctional kinases are implicated in diseases like cancer, leading to kinase inhibitor development.
  • Kinase inhibitors' specificity is vital, but off-target effects can impair drug efficacy.

Purpose of the Study:

  • To review major kinases affecting mitochondrial signaling.
  • To discuss strategies for targeting kinase activities in cancer and mitochondrial function.
  • To explore the potential of mitochondrial bioenergetics in predicting drug effects.

Main Methods:

  • Literature review of kinase functions and mitochondrial signaling.
  • Analysis of pharmacological strategies targeting kinases and mitochondria.
  • Discussion of cell-based assays for monitoring mitochondrial bioenergetics.

Main Results:

  • Selected major kinases significantly impact mitochondrial signaling pathways.
  • Kinase inhibition can converge on mitochondria, affecting cellular energy.
  • Pharmacological strategies aim to redirect mitochondrial function in cancer therapy.

Conclusions:

  • Understanding kinase-mitochondria interactions is key for cancer drug development.
  • Cell-based mitochondrial bioenergetic recordings can predict kinase inhibitor off-target effects.
  • Targeting mitochondrial function offers a strategy to enhance cancer therapy specificity.